For the Inventor, By the Inventor

Enter assignee name

Leiden, Netherlands

Crucell Holland B.v.

USPTO Granted Patents = 146

CIPO Patents = 104

EPO Patents = 55

Trademarks = 2

Forward Citations = 2,153

Loading Chart...

Loading Chart...

261 inventors (with patents filed for the assignee):

Ronald Vogels (37 out of 50 patents)

Abraham Bout (33 out of 55 patents)

Cornelis Adriaan De Kruif (24 out of 49 patents)

4. Maria Grazia Pau (18 out of 30 patents)

5. Mark Throsby (17 out of 46 patents)

6. Menzo Jans Emco Havenga (16 out of 16 patents)

7. Lennart Holterman (11 out of 11 patents)

8. Govert Johan Schouten (10 out of 17 patents)

9. Alphonsus G C M UytdeHaag (10 out of 10 patents)

10. Menzo Havenga (9 out of 9 patents)

11. Alexander Berthold Hendrik Bakker (8 out of 16 patents)

12. Ton Logtenberg (7 out of 56 patents)

13. Jorn Kaspers (7 out of 7 patents)

14. Antonius J H Stegmann (7 out of 8 patents)

15. Domenico Valerio (7 out of 21 patents)

Core Competencies:

Human Binding Molecules

Influenza Virus Neutralization

Adenoviral Vectors

Respiratory Syncytial Virus Antibodies

Recombinant Vaccines

Viral Purification

Malaria Vaccination

Poliovirus Production

Cancer Treatment Molecules

Immunoglobulin Libraries

Tuberculosis Vaccination

Sialylation Techniques

146 patents: Sort by Forward Citations

1. 9611317 - Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof (2017-04-04),

2. 9428768 - Method for the production and purification of adenoviral vectors (2016-08-30),

3. 9403900 - Anti-human respiratory syncytial virus (RSV) antibodies and methods of use (2016-08-02),

4. 9365638 - Antibodies against human respiratory syncytial virus (RSV) and methods of use (2016-06-14),

5. 9228205 - Complementing cell lines (2016-01-05),

6. 9200064 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-12-01),

7. 9168292 - Heterologous prime boost vaccination regimen against malaria (2015-10-27),

8. 9139642 - Anti-human respiratory syncytial virus (RSV) antibodies and methods of use (2015-09-22),

9. 9125870 - Vaccine against RSV (2015-09-08),

10. 9119813 - Vaccine against RSV (2015-09-01),

11. 9109017 - Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof (2015-08-18),

12. 9022240 - Production of poliovirus at high titers for vaccine production (2015-05-05),

13. 9011848 - Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof (2015-04-21),

14. 9005624 - Binding molecules capable of neutralizing rabies virus and uses thereof (2015-04-14),

15. 9005621 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-04-14),

Crucell Holland B.V. is a biopharmaceutical company specializing in the development, production, and marketing of vaccines and antibodies for infectious diseases. With a strong emphasis on research and innovation, Crucell aims to provide effective and affordable solutions to global health challenges. The company operates globally, partnering with governments, organizations, and other pharmaceutical companies to address pressing healthcare issues.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

146 Patents

#1 in Leiden

#62 in Netherlands

#5,416 in the World

Leiden, Netherlands

Crucell Holland B.v.

Forward Citations = 2,153

261 inventors:

Ronald Vogels (37 out of 50 patents)

Abraham Bout (33 out of 55 patents)

Cornelis Adriaan De Kruif (24 out of 49 patents)

4. Maria Grazia Pau (18 out of 30 patents)

5. Mark Throsby (17 out of 46 patents)

Please report any incorrect information to support@idiyas.com

Loading…